Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Amgen · NCT07590193

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
162
US sites recruiting
2
Study start
June 11, 2026
Record last updated
August 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).

Being studied: AMG 127; Placebo

Conditions: Diabetes Mellitus, Type 2

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria for Part A and B

  • Participant must be 18-65 years of age
  • Participant must be overtly healthy

Inclusion Criteria for Part C

  • Participant must be 40-75 years of age
  • Confirmed diagnoses of T2DM

Exclusion Criteria for Part A and B

  • History of hypotension, syncope, or orthostatic intolerance
  • Systolic blood pressure >140 millimeters of mercury (mmHg) or diastolic blood pressure >90 mmHg

Exclusion Criteria for Part C

  • Hemoglobin A1c (HbA1c) >10% within the last 3 months
  • History of hypotension, syncope, or orthostatic intolerance
  • Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg

Recruiting US locations

Study contacts (from the official record)

  • Amgen Call Center · 866-572-6436 · medinfo@amgen.com
All diabetes studies in California →
A Trial Evaluating AMG 127 in Healthy Participants and… (NCT07590193) | Bored Studies